arrow
A

Andrea T. Hooper

regeneron pharmaceuticals inc
H指数:40
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

2型炎症性疾病共享共病、分子特征、IL4/IL13遗传学以及对IL4/IL13阻断剂的反应

2026-05-140
OAAI
Unraveling the Dynamic Interplay of SARS-CoV-2 Neutralizing Monoclonal Antibodies and Host Immunity in Hospitalized Patients with COVID-19
2025-11-010
PRE
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

伊特佩克单抗(itepekimab)和杜匹鲁单抗(dupilumab)这两种针对IL-33和IL-4Rα的阻断抗体,能够调节哮喘中既独特又共同的炎症介质。

2025-10-290
PRE
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

Dupilumab作为花生过敏患儿口服免疫治疗的辅助手段

2024-12-140
PRE
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
2024-12-140
OAAI
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
2024-11-060
PRE
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19

CAS IMD单克隆抗体鸡尾酒对住院新型冠状病毒肺炎患者的潜在免疫调节作用

2024-10-010
PRE
Pre-hospital ECPR in an Australian metropolitan setting: a single-arm feasibility assessment-The CPR, pre-hospital ECPR and early reperfusion (CHEER3) study

澳大利亚大都市环境中的院前ECPR: 单臂可行性评估-CPR,院前ECPR和早期再灌注 (CHEER3) 研究

2023-12-1311
OAAI
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
2023-06-1718
OAAI
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial
2023-04-191
OAAI
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

Casirivimab和Imdevimab治疗可降低血清阳性的非中和或临界中和抗体的住院新型冠状病毒肺炎患者的病毒载量并改善临床结局

MBIO
IF4.7
2022-12-207
OAAI
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
2022-10-0125
OAAI
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

Casirivimab和Imdevimab用于治疗住院新型冠状病毒肺炎患者

2022-07-2733
OAAI
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

纤连蛋白抗体-药物偶联物的抗外域B剪接变体与检查点阻断相结合可消除肿瘤,并提高疗效

2022-07-069
OAAI